Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Acquires 129,000 Shares

Key Points

• Director Aharon Schwartz of Protalix BioTherapeutics purchased 129,000 shares at an average price of $1.60, increasing his holdings by 74.14% to a total of 303,000 shares.
• Protalix BioTherapeutics has a market capitalization of approximately $130.56 million, with shares trading at $1.64, showing a recent increase despite having a 12-month low of $0.82.
• Institutional investors have significantly increased their stakes, with JPMorgan Chase & Co. raising its position by over 2000% in the second quarter.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report) Director Aharon Schwartz bought 129,000 shares of the stock in a transaction dated Tuesday, June 10th. The shares were acquired at an average price of $1.60 per share, for a total transaction of $206,400.00. Following the completion of the purchase, the director directly owned 303,000 shares in the company, valued at approximately $484,800. This trade represents a 74.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Protalix BioTherapeutics Stock Performance

Shares of PLX stock traded down $0.04 during trading on Friday, hitting $1.48. 702,056 shares of the company were exchanged, compared to its average volume of 846,234. Protalix BioTherapeutics, Inc. has a twelve month low of $0.89 and a twelve month high of $3.10. The firm has a market capitalization of $117.82 million, a price-to-earnings ratio of -11.38 and a beta of -0.21. The business's 50-day simple moving average is $1.49 and its 200 day simple moving average is $2.04.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th.

Hedge Funds Weigh In On Protalix BioTherapeutics

Several institutional investors have recently modified their holdings of PLX. Renaissance Technologies LLC raised its position in shares of Protalix BioTherapeutics by 17.0% during the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock worth $2,102,000 after acquiring an additional 162,100 shares during the last quarter. Marshall Wace LLP purchased a new stake in Protalix BioTherapeutics in the 4th quarter worth approximately $192,000. Northern Trust Corp lifted its stake in shares of Protalix BioTherapeutics by 1,299.4% in the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company's stock valued at $1,376,000 after purchasing an additional 679,451 shares during the period. Jane Street Group LLC grew its holdings in shares of Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company's stock worth $214,000 after acquiring an additional 67,664 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its holdings in Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock worth $55,000 after buying an additional 5,686 shares during the period. 16.53% of the stock is currently owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.